Prognostic score to test the risk of AIHA development over time. Patients were divided into low risk (not unfavorable cytogenetics and M IGHV), intermediate risk (unfavorable cytogenetics or UM IGHV) and high risk (unfavorable cytogenetics and UM IGHV).